|Summary sheet: 4-AcO-DET|
|Common names||4-AcO-DET, 4-Acetoxy-DET, Ethacetin|
|Systematic name||3-(2-(Diethylamino)ethyl)-1H-indol-4-yl acetate|
|Routes of Administration|
4-AcO-DET (4-Acetoxy-N,N-diethyltryptamine, ethacetin) is a lesser-known novel psychedelic substance of the tryptamine class. It is chemically related to psilocin and part of a series of substituted tryptamines that includes 4-AcO-MET and 4-AcO-DMT.
There is very little data on the human pharmacology or toxicity of 4-AcO-DET, although analytical methods have been developed for its detection. It remains relatively rare and has very little documented history of human usage. It is highly advised to use harm reduction practices if using this substance.
4-AcO-DET, or 4-Acetoxy-N.N-diethyltryptamine, is a synthetic indole alkaloid molecule of the tryptamine class. Tryptamines share a core structure comprised of a bicylic indole heterocycle attached at R3 to an amino group via an ethyl side chain. 4-AcO-DET is substituted at R4 of its indole heterocycle with an acetoxy (AcO) functional group CH3COO−. It also contains two ethyl chains bound to the terminal amine RN of its tryptamine backbone (DET).
4-AcO-DET is the N-substituted diethyl homolog of 4-HO-DMT (psilocin). 4-AcO-DET is the acetate ester analog of DET and the N-substituted diethyl analog of 4-AcO-DMT. It is a higher homolog of 4-AcO-DMT and 4-AcO-MET.
4-substituted acetylated tryptamines such as 4-AcO-DET, 4-AcO-MET, and 4-AcO-DMT are hypothesized to principally act as a prodrug for their respective hydrolyzed counterparts (e.g. 4-HO-DMT, 4-HO-MET and 4-HO-DET). In theory, they would become inactive until they are deacetylated in the body, although there is on-going discussion as to whether they might display their own intrinsic activity.
Like with most psychedelic tryptamines, 4-AcO-DET is thought to act principally as a 5-HT2A partial agonist. The psychedelic effects are believed to come from 4-AcO-DET's binding efficacy at the 5-HT2A receptors.
However, the role of these interactions and how they result in the psychedelic experience continues to remain elusive.
Disclaimer: The effects listed below cite the Subjective Effect Index (SEI), an open research literature based on anecdotal user reports and the personal analyses of PsychonautWiki contributors. As a result, they should be viewed with a healthy degree of skepticism.
It is also worth noting that these effects will not necessarily occur in a predictable or reliable manner, although higher doses are more liable to induce the full spectrum of effects. Likewise, adverse effects become increasingly likely with higher doses and may include addiction, severe injury, or death ☠.
- Sedation and Stimulation - In terms of its effects on the physical energy levels of the user, 4-AcO-DET is typically relaxing, stoning and mildly sedating, although it can also sometimes be very stimulating and give users a "wired" feeling. This sense of sedation is often accompanied by uncontrollable yawning.
- Spontaneous physical sensations - The "body high" of 4-AcO-DET can be described as a pleasurable, warm, soft and all-encompassing tingling sensation. This maintains a consistent presence that steadily rises with the onset and hits its limit once the peak has been reached. Unlike other 4-substituted tryptamines, 4-AcO-DET is capable of being more stimulating and anxiety-inducing.
- Appetite suppression
- Bodily pressures
- Excessive yawning
- Pupil dilation
- Runny nose
- Watery eyes
- Abnormal heartbeat
- Difficulty urinating or Frequent urination
- Watery eyes
- Increased bodily temperature
- Muscle contractions
- Restless leg syndrome
- Stomach bloating
- Stomach cramps
- Teeth grinding
- Drifting (melting, breathing, morphing and flowing)
- Colour shifting
- Depth perception distortions
- Perspective distortions
- Symmetrical texture repetition
- After images
- Brightness alteration
The visual geometry that is present throughout this trip can be described as more similar in appearance to that of LSD, 2C-B or 2C-E than that of 4-AcO-DMT and ayahuasca. It can be comprehensively described through its variations as intricate in complexity, abstract in form, synthetic in style, structured in organization, brightly lit and multicoloured in scheme, glossy in shading, soft in edges, large in size, slow in speed, smooth in motion, rounded in corners, non-immersive in depth and consistent in intensity. The visuals have a very "artificial" feel to them and at higher dosages are significantly more likely to result in states of level 8A visual geometry over level 8B.
4-AcO-DET and its various other forms can produce a full range of high level hallucinatory states in a fashion that is more consistent and reproducible than that of many other commonly used psychedelics. These effects generally include:
- Internal hallucination (autonomous entities; settings, sceneries, and landscapes; perspective hallucinations and scenarios and plots) - This effect is very consistent in dark environments at appropriately high dosages. They can be comprehensively described through their variations as lucid in believability, interactive in style, new experiences in content, autonomous in controllability, geometry-based in style and almost exclusively of a personal, religious, spiritual, science-fiction, fantasy, surreal, nonsensical or transcendental nature in their overall theme.
Much like its hydroxylated counterpart 4-HO-DET, the cognitive effects of 4-AcO-DET are described by many as being relatively complex and unpredictable in style when compared to other commonly used psychedelics such as LSD or 2C-B which tend to be energetic and stimulating. It contains a notable number of typical and unique psychedelic cognitive effects.
The most prominent of these typical effects generally include:
- Analysis enhancement
- Conceptual thinking
- Autonomous voice communication
- Déjà vu
- Emotion enhancement
- Enhancement and suppression cycles - This can be described as constant waves of extremely stimulated and profound thinking which are spontaneously surpassed in a cyclic fashion by waves of general thought suppression and mental intoxication. These two states seem to switch between each other in a consistent loop once every 20 - 60 minutes.
- Feelings of interdependent opposites
- Perception of predeterminism
- Immersion enhancement
- Increased music appreciation
- Memory suppression
- Novelty enhancement
- Personal bias suppression
- Thought connectivity
- Thought loops
- Time distortion
- Unity and interconnectedness
There are currently no anecdotal reports which describe the effects of this compound within our experience index. Additional experience reports can be found here:
Toxicity and harm potential
The toxicity and long-term health effects of recreational 4-AcO-DET has not been studied in any scientific context and the exact toxic dose is unknown. This is because 4-AcO-DET is a research chemical with a very limited history of human usage. However, it is assumed to have a similar toxicity profile as psilocybin due to their structural similarity.
Anecdotal reports from those who have tried 4-AcO-DET suggests that there are no negative health effects attributed to simply trying the substance by itself at low to moderate doses and using it very sparingly (but nothing can be completely guaranteed). Independent research should always be done to ensure that a combination of two or more substances is safe before consumption.
It is strongly recommended that one use harm reduction practices when using this substance.
Tolerance and addiction potential
Although no formal studies have been conducted, it is believed that 4-AcO-DET is not habit-forming and the desire to use it can actually decrease with use.
Tolerance to the effects of 4-AcO-DET is built almost immediately after ingestion. After that, it takes about 3 days for the tolerance to be reduced to half and 7 days to be back at baseline (in the absence of further consumption). 4-AcO-DET presents cross-tolerance with all psychedelics, meaning that after the consumption of 4-AcO-DET all psychedelics will have a reduced effect.
Warning: Many psychoactive substances that are reasonably safe to use on their own can suddenly become dangerous and even life-threatening when combined with certain other substances. The following list provides some known dangerous interactions (although it is not guaranteed to include all of them).
Always conduct independent research (e.g. Google, DuckDuckGo, PubMed) to ensure that a combination of two or more substances is safe to consume. Some of the listed interactions have been sourced from TripSit.
- Lithium - Lithium is commonly prescribed for the treatment of bipolar disorder. There is a large body of anecdotal evidence that suggests taking it with psychedelics significantly increases the risk of psychosis and seizures. As a result, this combination is strictly discouraged.
- Cannabis - Cannabis may have an unexpectedly strong and unpredictable synergy with the effects of 4-AcO-DET. Caution is advised with this combination as it can significantly increase the risk of adverse psychological reactions like anxiety, paranoia, panic attacks, and psychosis. Users are advised to start off with only a fraction of their normal cannabis dose and take long breaks between hits to avoid unintentional overdose.
- Stimulants - Stimulants like amphetamine, cocaine or methylphenidate affect many parts of the brain and alter dopaminergic function. This combination can increase the risk of anxiety, paranoia, panic attacks, and thought loops. This interaction may also result in an elevated risk of mania and psychosis.
- Tramadol - Tramadol is well-documented to lower the seizure threshold and psychedelics may act to trigger seizures in susceptible individuals.
This legality section is a stub.
As such, it may contain incomplete or wrong information. You can help by expanding it.
Due to its relative obscurity, the possession and sale of 4-AcO-DET is unscheduled in most countries.
- Germany: Because it is an ester of DET, 4-AcO-DET is controlled under Anlage I BtMG (Narcotics Act, Schedule I) as of January 24, 1974. It is illegal to manufacture, possess, import, export, buy, sell, procure or dispense it without a license.
- Japan: 4-AcO-DET is a controlled substance in Japan effective July 29th, 2015.
- Switzerland: 4-AcO-DET is a controlled substance specifically named under Verzeichnis E.
- Sweden: 4-AcO-DET was classified under the Act on the Prohibition of Certain Goods Dangerous to Health on November 1, 2005, making it illegal to sell or possess.
- Turkey: 4-AcO-DET is a classed as drug and is illegal to possess, produce, supply, or import.
- United Kingdom: 4-AcO-DET is a Class A drug in the UK as it is an ester of the drug 4-HO-DET, which is a Class A drug as a result of the tryptamine catch-all clause.
- United States: 4-AcO-DET is unscheduled in the United States. It may be considered an analogue of psilocin (4-HO-DMT) which is a Schedule I drug under the Controlled Substances Act. As such, the sale for human consumption or the use for illicit non-medical or industrial intents and purposes could be prosecuted as crimes under the Federal Analogue Act.
- Takahashi, M.; Nagashima, M.; Suzuki, J.; Yasuda, I; Yoshida, T. (February 15, 2009). "Creation and application of psychoactive designer drugs data library using liquid chromatography with photodiode array spectrophotometry detector and gas chromatography–mass spectrometry". 77 (4): 1245–1272. doi:10.1016/j.talanta.2008.07.062. eISSN 1873-3573. ISSN 0039-9140. OCLC 01767116. PMID 19084633.
- "Compound Summary - 3-(2-(Diethylamino)ethyl)-1H-indol-4-yl acetate". PubChem. Retrieved July 18, 2020.
- Talaie, H.; Panahandeh, R.; Fayaznouri, M. R.; Asadi, Z.; Abdollahi, M. (2009). "Dose-independent occurrence of seizure with tramadol". Journal of Medical Toxicology. 5 (2): 63–67. doi:10.1007/BF03161089. ISSN 1556-9039.
- "Betäubungsmittelgesetz (BtMG) Anlage I" [Narcotics Act (BtMG) Schedule I] (in German). Bundesamt für Justiz [Federal Office of Justice]. Retrieved December 10, 2019.
- "Sechste Verordnung über die den Betäubungsmitteln gleichgestellten Stoffe" (PDF). Bundesgesetzblatt Jahrgang 1974 Teil I Nr. 6 (in German). Bundesanzeiger Verlag [Federal Gazette] (published January 23, 1974). January 17, 1974. p. 97. eISSN 0344-7634.
- "Betäubungsmittelgesetz (BtMG) § 29" [Narcotics Act (BtMG) § 29] (in German). Bundesamt für Justiz [Federal Office of Justice]. Retrieved December 10, 2019.
- 危険ドラッグの成分４物質を新たに指定薬物に指定 (in Japanese), 厚生労働省 [Ministry of Health, Labour and Welfare (MHLW)], retrieved 2 May 2022
- "Verordnung des EDI über die Verzeichnisse der Betäubungsmittel, psychotropen Stoffe, Vorläuferstoffe und Hilfschemikalien" (in German). Bundeskanzlei [Federal Chancellery of Switzerland]. Retrieved January 1, 2020.
- "Förordning om ändring i förordningen (1999:58) om förbud mot vissa hälsofarliga varor" (PDF). Svensk författningssamling (in Swedish). Läkemedelsverket [Medical Products Agency] (published October 18, 2005). October 6, 2005. ISSN 1101-5225. SFS 2005:733.
- "Bakanlar Kurulu Kararı - Karar Sayısı : 2013/5742" (in Turkish). Başbakanlık Mevzuatı Geliştirme ve Yayın Genel Müdürlüğü [General Directorate of Legislation Development and Publication] (published January 25, 2014). December 16, 2013.
- "Kararnamenin Eki: Liste" (PDF). Resmî Gazete, Sayı: 28893 (in Turkish). Başbakanlık Mevzuatı Geliştirme ve Yayın Genel Müdürlüğü [General Directorate of Legislation Development and Publication] (published January 25, 2014). December 16, 2013. 2013/5742.
- "Schedule 2: Part I: Class A Drugs". "Misuse of Drugs Act 1971". UK Government. Retrieved January 7, 2020.